Results: A total of 45 studies were eligible (20 RCTs and 25 observational studies). All IV preparations resulted in significant improvements in haematological parameters, with a median increase of 21.8 g/L at 3-4 weeks and 30.1 g/L by delivery. When separated according to dose administered, a greater median increase in Hb was observed with a high (25 g/L; range 20-39.6 g/L) compared with low dose (20 g/L; range 6.2-50.3 g/ L). The median prevalence of ADRs for IPM (2.2%; range 0-4.5%) was slightly lower than FCM (5.0%; range 0-20%) and IS (6.7%; range 0-19.5%).
STRATEGIES TO REDUCE MEDICATION ERRORS IN
Robinson Research Institute, University of Adelaide Background: Neonates are more prone to medication errors at each stage of the medicine management process due to the increased need for calculations, dilutions, and manipulations of medications, many of which are only available in adult formulations and concentrations.
Methods: Systematic review of all controlled or noncontrolled studies, in any language, identified from searches of PudMed, Embase, MedLine and reference list checking. Eligible studies were those investigating the impact of any medication safety strategies aimed at reducing medication errors in neonates in the hospital setting.
Results: A total of 108 studies met the inclusion criteria, including 87 controlled and 21 non-controlled studies; 40 studies were undertaken solely in a neonatal setting. Medication safety strategies were classified into six themes; multifactorial (n = 20), technology (n = 40), hazard risk analysis (n = 8), personnel (n = 13), clinical pharmacy (n = 9) and organisational (n = 18). Overall, the majority (n = 75; 70%) of medication safety strategies led to a reduction in medication errors, while for 29 studies (27%) the impact was uncertain, largely due to lack of adequate comparator groups or indirect measurement of medication errors.
Conclusion: No one single strategy appeared superior, with significant variability evident among studies within and across themes with respect to methods, definitions, outcomes, and potential risk of bias. Further research is required to evaluate the relative costeffectiveness of the various medication safety strategies to facilitate decisions regarding uptake and implementation into clinical practice. Methods: Retrospective cohort study of all pregnant women administered intravenous iron polymaltose (IPM) between January 2014 and January 2016 at a Tertiary teaching hospital in Adelaide, Australia. Data on maternal characteristics, intravenous iron infusion details, and haematological parameters were collected from case notes and electronic records. Main outcome measures included indication for intravenous iron infusion, prevalence of infusion reactions, change in haemoglobin, and correction of anaemia prior to delivery Results: Intravenous IPM was administered in 213 pregnancies, 62.0% of women with iron deficiency anaemia (IDA) and the remainder (38.0%) with non-anaemic iron deficiency. Adverse reactions occurred in 24% of women, of which 32% required infusion cessation. Anaemia was still present at delivery among 7%, and 17% of women with mild, and moderate/severe anaemia respectively. Approximately 1 in 5 anaemic women received an IV IPM dose below that recommended by the local guideline, particularly in women with a BMI ?25 kg/m 2 compared with <25 kg/m 2 (30.9% vs. 6.3%; p < 0.001). Doses 'at or above recommended' resulted in a greater increase in haemoglobin from treatment until delivery than doses 'below recommended' (adjusted beta coefficient 8.4 g/L; 95%CI 2.7 to 14.1 g/L).
USE OF INTRAVENOUS IRON POLYMALTOSE IN THE

Conclusion:
Intravenous IPM is effective in treating iron deficiency anaemia in pregnancy but is associated with a high prevalence of adverse drug reactions (ADR) and treatment cessation. Findings of this study highlight the need for further research on the treatment of non-anaemic iron deficiency and IV iron dose optimisation during pregnancy. School of Nursing and Midwifery, Monash University Background: In Brunei Darussalam, health professionals have observed that pregnant women, including those with hypertensive disorders of pregnancy (HDP), do not always seek healthcare and may be reluctant to follow recommended treatments. This may, in part be related to women's lack of knowledge about signs and symptoms of pregnancy-related complications, including HDP.
KNOWLEDGE OF SIGNS AND SYMPTOMS OF HYPERTENSIVE DISORDERS OF PREGNANCY AMONG
Objective: To explore pregnant women's knowledge of signs and symptoms of HDP when they were first diagnosed with a HDP.
Methods: We surveyed pregnant women with HDP who attended the antenatal clinics at three selected government hospitals in Brunei Darussalam.
Result: We had a response rate of 74% (104/140). Most of these women listed one (n = 24, 24%), two (n = 29, 29%) or
